RhumbLine Advisers
TXG icon

RhumbLine Advisers’s 10x Genomics TXG Stock Holding History

RhumbLine Advisers’s Portfolio TXG Stock Details TXG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.77M Buy
150,423
+7,044
+5% +$185K ﹤0.01% 1401
2026
Q1 		$3.04M Sell
143,379
-61
-0% -$1.22K ﹤0.01% 1643
2025
Q4 		$2.34M Sell
143,440
-19,341
-12% -$292K ﹤0.01% 1787
2025
Q3 		$1.9M Sell
162,781
-2,758
-2% -$36K ﹤0.01% 1939
2025
Q2 		$1.92M Buy
165,539
+45,049
+37% +$411K ﹤0.01% 1909
2025
Q1 		$1.05M Buy
120,490
+12,374
+11% +$156K ﹤0.01% 2149
2024
Q4 		$1.55M Sell
108,116
-1,641
-1% -$25.9K ﹤0.01% 2016
2024
Q3 		$2.48M Buy
109,757
+2,785
+3% +$57.6K ﹤0.01% 1792
2024
Q2 		$2.08M Buy
106,972
+65
+0.1% +$1.7K ﹤0.01% 1859
2024
Q1 		$4.01M Sell
106,907
-14,975
-12% -$658K ﹤0.01% 1535
2023
Q4 		$6.82M Buy
121,882
+475
+0.4% +$20.7K 0.01% 1245
2023
Q3 		$5.01M Buy
121,407
+718
+0.6% +$37.4K 0.01% 1344
2023
Q2 		$6.74M Buy
120,689
+12,321
+11% +$667K 0.01% 1208
2023
Q1 		$6.05M Buy
108,368
+7,039
+7% +$329K 0.01% 1216
2022
Q4 		$3.69M Buy
101,329
+5,775
+6% +$189K 0.01% 1454
2022
Q3 		$2.72M Buy
95,554
+10,920
+13% +$416K ﹤0.01% 1604
2022
Q2 		$3.83M Buy
84,634
+13,457
+19% +$698K 0.01% 1398
2022
Q1 		$5.41M Sell
71,177
-7,521
-10% -$658K 0.01% 1257
2021
Q4 		$11.7M Buy
78,698
+2,607
+3% +$399K 0.01% 904
2021
Q3 		$11.1M Sell
76,091
-749
-1% -$129K 0.02% 897
2021
Q2 		$15M Buy
76,840
+19,354
+34% +$3.5M 0.02% 764
2021
Q1 		$10.4M Sell
57,486
-1,109
-2% -$192K 0.01% 964
2020
Q4 		$8.3M Sell
58,595
-349
-0.6% -$50.6K 0.01% 1047
2020
Q3 		$7.35M Sell
58,944
-1,282
-2% -$135K 0.01% 932
2020
Q2 		$5.38M Buy
+60,226
New +$4.69M 0.01% 1169

Other funds holding TXG

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
QCM
Quantinno Capital Management New York $83.3B AUM 37.97% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

RhumbLine Advisers's TXG Position: Q2 2026 in Review

RhumbLine Advisers increased its 10x Genomics (TXG) stake by 4.9% in Q2 2026, buying an estimated $185K and bringing the position to 150,423 shares worth $5.77M. The position accounts for ﹤0.01% of the portfolio, ranked #1401.

RhumbLine Advisers first reported a position in TXG in Q2 2020 and has held it in 25 quarters since. The position peaked at $15M in Q2 2021. 393 funds tracked by Wall St. Rank hold TXG as of Q2 2026.

  • RhumbLine Advisers held 150,423 shares of 10x Genomics worth $5.77M as of Q2 2026.
  • RhumbLine Advisers bought 7,044 10x Genomics shares in Q2 2026, an estimated $185K.
  • 10x Genomics made up ﹤0.01% of RhumbLine Advisers's portfolio in Q2 2026, its #1401 holding.
  • RhumbLine Advisers first reported a position in 10x Genomics in Q2 2020 and has held it in 25 quarters since.
  • RhumbLine Advisers's 10x Genomics position peaked at $15M in Q2 2021.
  • 393 funds tracked by Wall St. Rank held 10x Genomics as of Q2 2026.

Based on RhumbLine Advisers's 13F filing for Q2 2026, filed 12 Aug 2026.